London, November 26, 2024 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Entia and is pleased to announce the placement of Timothy Broke-Smith as Senior Vice President of Partnerships.
Europa Biosite is pleased to announce the acquisition of AMSBIO, a premier supplier of life science products and services, with expertise in the areas of biospecimens, stem cell research, 3D cell culture, glycobiology, and molecular biology. Headquartered in Oxford, UK, and with offices in both the USA and the Netherlands, AMSBIO serves life science researchers across Europe and throughout North America.
A new industry briefing note developed by Pioneer Group in collaboration with the UK chemicals sector community highlights the urgent need for the sector to transition to a more sustainable, circular economy.
The paper, developed at a ‘Pioneer Presents’ workshop held at the Wilton Centre, Tees Valley, earlier this year, outlines the environmental challenges associated with the sector’s current reliance on fossil resources, the potential of sustainable carbon feedstocks, and the significant actions required to transform the UK chemicals industry.
Established in 2000, LBIC provides a focus for life science activity in London, offering laboratory and office facilities as well as a virtual service to meet the needs of a wide range of organisations, from micro businesses to multi-national corporations. LBIC is owned and operated by the prestigious Royal Veterinary College (RVC), the UK’s largest and longest-established veterinary institution. LBIC will soon expand into an additional building to offer further opportunities for companies.
London, November 21, 2024 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, recently partnered with Solu Therapeutics (Solu) and is pleased to announce the placement of Sergio Santillana, MD, MSc, MBA, as Chief Medical Officer (CMO).
Solu Therapeutics is a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas.
Significant CRO C-suite experience expected to drive growth and commercial expansion into global markets
Main Purpose of the Job
The role of the Commercialisation Manager is to support the Head of BDI in delivering Knowledge Exchange, Commercialisation, and Impact Strategies. The successful applicant will bring their own experience, expertise and professional networks to help Earlham to deliver knowledge exchange activities and generate impact.
Medicilon's preclinical pharmacology and toxicology research team is equipped with a professional send format conversion team and has established a send data conversion platform that is fully developed in terms of software, technology, specification and quality, to realize accurate data conversion and provide a good environment for electronic data submission. In recent years, Medicilon SEND team helped customers complete many send data conversion projects within very tight timeline and filed timely with FDA.
Patents directed to medical devices can be of great commercial value. However, claims relating to medical devices can fall foul of the European patent office’s statutory exclusions of medical methods, so care needs to be taken both during drafting and prosecution at the EPO. This webinar will discuss some of the issues faced in applications relating to medical devices at the EPO, and provide guidance on how to optimise claim coverage.
Topics will include:
• An overview of EPO exclusions from patentability relevant to medical devices